Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of concomitant hexavalent infant vaccine with MenC vaccine
2012-005547-24Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Hexyon and meningococcal serogroup C conjugate vaccine in Preventable infectious diseases (VPD) (2 arms), sponsored by Sanofi. Primary endpoint: Primary series immunogenicity and safety. Started Jan 2013; status: completed.
02
Drugs
Hexyonmeningococcal serogroup C conjugate vaccine
03
Conditions
Preventable infectious diseases (VPD)
Beyond the preview
Go deeper on 2012-005547-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005547-24.